Search results
Results from the WOW.Com Content Network
The Mérieux family is an entrepreneurial dynasty from Lyon, France, owners of the Institut Mérieux holding, founders of companies such as Sanofi Pasteur, bioMérieux (in vitro diagnostics) and Mérial (veterinary activity), but also of the foundations Fondation Marcel-Mérieux and Fondation Christophe et Rodolphe Mérieux, of the Jean Mérieux P4 laboratory and of humanitarian organisation ...
Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur. 2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their ...
The vaccine development branch of the institute was separated early on and is now part of Sanofi Pasteur. [ 1 ] , [ 2 ] , [ 3 ] The current name was changed in 2009 from Mérieux Alliance. [ 1 ] The holding is owned through the Mérieux Alliance company at 68% by Alain and Alexandre Mérieux and at 32% by the Christophe and Rodolphe Mérieux ...
Two class action lawsuits have been filed charging Sanofi Pasteur Inc. with violating U.S. antitrust laws, as a result of its bundling practices. [10] [11] The suits challenge Sanofi's alleged “anticompetitive scheme” [12] to maintain its monopoly in the U.S. meningitis vaccine market. [13] [14] These lawsuits have since been consolidated. [15]
In 2005, Sanofi Pasteur, ... The Aventis Foundation, a German charitable trust, was established in 1996, as the Hoechst Foundation, with an endowment of €50 million ...
CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline, [9] [10] Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative, [11] and ...
Sanofi Biogenius Canada was founded in 1992 by Sanofi Pasteur to engage younger students in biotechnology education. [2]The program is managed by Partners in Research, on behalf of Sanofi Pasteur and Sanofi Canada, and in partnership with science outreach and biotechnology industry organizations across Canada.
Working with Brazil's Butantan Institute, the U.S. National Institute of Health, and Sanofi Pasteur, PDVI provided technical advice and support for the efficacy and clinical trials of their respective dengue vaccine candidates and established a consortium of field sites in dengue-endemic countries across Asia and the Americas.